News and updates
September 3, 2020
AMRI Selected to Support AstraZeneca in Delivery of COVID-19 Vaccine
Albany Molecular Research, Inc. (AMRI), a leading global provider of advanced drug development and manufacturing solutions, today announced that it has signed a supply agreement with AstraZeneca to support the manufacture of AstraZeneca’s COVID-19...
August 3, 2020
Tryp Therapeutics Partners With Albany Molecular Research Inc. To Manufacture a Proprietary Psilobycin-Based Drug
Tryp Therapeutics Inc. (“Tryp” or the “Company”), a clinical-stage pharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, announced today it has entered into an agreement with Albany Molecular Researc...
July 8, 2020
ViralClear Pharmaceuticals Partners with AMRI on the Manufacture of Merimepodib API in Development for the Potential Treatment of COVID-19
ViralClear Pharmaceuticals, Inc. (ViralClear), supported by Albany Molecular Research Inc., (AMRI), a leading global contract research, development, and manufacturing organization (CDMO), is undertaking research to investigate the potential of meri...
June 11, 2020
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1 Synthesized by AMRI
BryoLogyx Inc. today announced it has entered into two agreements with Neurotrope, Inc. (Nasdaq: NTRP) to acquire Neurotrope’s preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurot...
April 30, 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
AMRI today announced its ongoing commitment to do its part in support of public health needs amidst the COVID-19 pandemic. The company continues to focus on the safety of its employees, assuring supply of critical raw materials, active pharmaceutica...
April 23, 2020
AMRI Leads the Industry in Highest Ranking from SafeBridge for Highly Potent Compound Safety
Albany Molecular Research Inc. (AMRI),announced today that the company’s manufacturing facility in Rensselaer, NY, has been designated “Industry Leader” as part of its re-certification under the SafeBridge® program for “Potent Compound...
April 22, 2020
SafeBridge Consultants Awards AMRI Industry Leader Potent Compound Safety Certification
SafeBridge® Consultants, Inc. (“SafeBridge”), headquartered in Mountain View, CA, announces today that the Albany Molecular Research, Inc. (AMRI) manufacturing facility in Rensselaer, NY, has been re-certified under SafeBridge’s Potent Compoun...
March 12, 2020
Willow Biosciences Announces Cannabinoid Scale-Up and Expedited Path to Commercialization
Willow Biosciences Inc. (“Willow” or “the Company“) (TSX: WLLW;OTCQB: CANSF), is pleased to announce that it has achieved its first major commercial milestone by delivering a proprietary cannabinoid-producing yeast strain to its scale-up...
December 2, 2019
John Ratliff Named CEO of AMRI
AMRI, a leading global pharmaceutical contract research, development and manufacturing organization, today announced that John Ratliff has been named as chief executive officer, effective today, Dec. 2, 2019. Ratliff succeeds Michael Mulhern, who has...
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.